PURPOSE: We aimed to develop a gallium-68 (Ga-68)-labeled single-chain variable fragment (scFv) targeting the human epidermal growth factor receptor 2 (HER2) to rapidly and noninvasively evaluate the status of HER2 expression. PROCEDURES: Anti-HER2 scFv was labeled with Ga-68 by using deferoxamine (Df) as a bifunctional chelate. Biodistribution of [(68)Ga]Df-anti-HER2 scFv was examined with tumor-bearing mice and positron emission tomography (PET) imaging was performed. The changes in HER2 expression after anti-HER2 therapy were monitored by PET imaging. RESULTS: [(68)Ga]Df-anti-HER2 scFv was obtained with high radiochemical yield after only a 5-min reaction at room temperature. The probe showed high accumulation in HER2-positive xenografts and the intratumoral distribution of radioactivity coincided with HER2-positive regions. Furthermore, [(68)Ga]Df-anti-HER2 scFv helped visualize HER2-positive xenografts and monitor the changes in HER2 expression after anti-HER2 therapy. CONCLUSION: [(68)Ga]Df-anti-HER2 scFv could be a promising probe to evaluate HER2 status by in vivo PET imaging, unless trastuzumab is prescribed as part of the therapy.
PURPOSE: We aimed to develop a gallium-68 (Ga-68)-labeled single-chain variable fragment (scFv) targeting the human epidermal growth factor receptor 2 (HER2) to rapidly and noninvasively evaluate the status of HER2 expression. PROCEDURES: Anti-HER2scFv was labeled with Ga-68 by using deferoxamine (Df) as a bifunctional chelate. Biodistribution of [(68)Ga]Df-anti-HER2scFv was examined with tumor-bearing mice and positron emission tomography (PET) imaging was performed. The changes in HER2 expression after anti-HER2 therapy were monitored by PET imaging. RESULTS: [(68)Ga]Df-anti-HER2scFv was obtained with high radiochemical yield after only a 5-min reaction at room temperature. The probe showed high accumulation in HER2-positive xenografts and the intratumoral distribution of radioactivity coincided with HER2-positive regions. Furthermore, [(68)Ga]Df-anti-HER2scFv helped visualize HER2-positive xenografts and monitor the changes in HER2 expression after anti-HER2 therapy. CONCLUSION: [(68)Ga]Df-anti-HER2scFv could be a promising probe to evaluate HER2 status by in vivo PET imaging, unless trastuzumab is prescribed as part of the therapy.
Authors: Tove Olafsen; Vania E Kenanova; Gobalakrishnan Sundaresan; Anne-Line Anderson; Desiree Crow; Paul J Yazaki; Lin Li; Michael F Press; Sanjiv S Gambhir; Lawrence E Williams; Jeffrey Y C Wong; Andrew A Raubitschek; John E Shively; Anna M Wu Journal: Cancer Res Date: 2005-07-01 Impact factor: 12.701
Authors: Richard P Baum; Vikas Prasad; Dirk Müller; Christiane Schuchardt; Anna Orlova; Anders Wennborg; Vladimir Tolmachev; Joachim Feldwisch Journal: J Nucl Med Date: 2010-05-19 Impact factor: 10.057
Authors: Jessica N McAlpine; Kimberly C Wiegand; Russell Vang; Bridgett M Ronnett; Anna Adamiak; Martin Köbel; Steve E Kalloger; Kenneth D Swenerton; David G Huntsman; C Blake Gilks; Dianne M Miller Journal: BMC Cancer Date: 2009-12-10 Impact factor: 4.430
Authors: S Chandarlapaty; M Scaltriti; P Angelini; Q Ye; M Guzman; C A Hudis; L Norton; D B Solit; J Arribas; J Baselga; N Rosen Journal: Oncogene Date: 2009-10-26 Impact factor: 9.867
Authors: Feng Chen; Kai Ma; Brian Madajewski; Li Zhuang; Li Zhang; Keith Rickert; Marcello Marelli; Barney Yoo; Melik Z Turker; Michael Overholtzer; Thomas P Quinn; Mithat Gonen; Pat Zanzonico; Anthony Tuesca; Michael A Bowen; Larry Norton; J Anand Subramony; Ulrich Wiesner; Michelle S Bradbury Journal: Nat Commun Date: 2018-10-08 Impact factor: 14.919